Prepping First DNA Methylation Dx for FDA, Epigenomics Moves PITX2 Test to GeneChip | GenomeWeb
Epigenomics said this week that it has transferred its prostate cancer classification assay to the Affymetrix GeneChip platform as it prepares to seek FDA approval for the test in the first quarter of 2007.
The tissue-based test, which measures the methylation status of the PITX2 gene to gauge the likelihood of post-prostatectomy relapse, could be the first DNA methylation-based diagnostic to win FDA approval, according to company officials. 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.